Early menopause and related vaginal atrophy is a well known side-effect of hormone adjuvant treatment in breast cancer patients, particularly during aromatase-inhibitors therapy. Due to estrogens contra-indication, proper therapy for such symptom remains often an inadequately addressed clinical problem. After an accurate assessment of the risk/benefit ratio, vaginal low-dose estrogen treatment (better with estradiol) may have a role in controlling vaginal atrophy in selected and informed breast cancer women.
- Breast cancer survivors
- Menopause treatment-related
- Tamoxifen and aromatase inhibitors therapy
- Vaginal estrogen therapy
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Obstetrics and Gynaecology